Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.

Saint-Jean A, Reguart N, Eixarch A, Adán A, Castellà C, Sánchez-Dalmau B, Sainz-de-la-Maza M.

J Fr Ophtalmol. 2018 Nov 22. pii: S0181-5512(18)30435-2. doi: 10.1016/j.jfo.2018.07.005. [Epub ahead of print]

PMID:
30473235
2.

Predictors of vision impairment in Multiple Sclerosis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, Sola-Valls N, Sepulveda M, Guerrero A, Alba S, Andorra M, Camos A, Sanchez-Vela L, Alfonso V, Saiz A, Villoslada P.

PLoS One. 2018 Apr 17;13(4):e0195856. doi: 10.1371/journal.pone.0195856. eCollection 2018.

3.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
4.

Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A.

Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. No abstract available.

5.

Phenytoin for neuroprotection.

Martinez-Lapiscina EH, Andorra M, Sanchez-Dalmau B, Villoslada P.

Lancet Neurol. 2016 Aug;15(9):901-902. doi: 10.1016/S1474-4422(16)30093-X. No abstract available.

PMID:
27478946
6.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
7.

Visual field impairment captures disease burden in multiple sclerosis.

Ortiz-Perez S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, Calbet D, Lampert EJ, Alba-Arbalat S, Guerrero-Zamora AM, Zubizarreta I, Sola-Valls N, Llufriu S, Sepúlveda M, Saiz A, Villoslada P, Martinez-Lapiscina EH.

J Neurol. 2016 Apr;263(4):695-702. doi: 10.1007/s00415-016-8034-2. Epub 2016 Feb 9.

PMID:
26860093
8.

Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH.

J Neurol. 2015 Nov;262(11):2491-7. doi: 10.1007/s00415-015-7876-3. Epub 2015 Aug 11.

PMID:
26259563
9.

Dynamics of retinal injury after acute optic neuritis.

Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2015 Mar;77(3):517-28. doi: 10.1002/ana.24351. Epub 2015 Feb 14.

PMID:
25559267
10.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.

Martínez-Lapiscina EH, Fraga-Pumar E, Gabilondo I, Martínez-Heras E, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Tercero A, Andorra M, Roca MF, Lampert E, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

BMC Res Notes. 2014 Dec 15;7:910. doi: 10.1186/1756-0500-7-910.

11.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A.

PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.

12.

The visual pathway as a model to understand brain damage in multiple sclerosis.

Martínez-Lapiscina EH, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe AI, Torres-Torres R, Villoslada P.

Mult Scler. 2014 Nov;20(13):1678-85. doi: 10.1177/1352458514542862. Epub 2014 Jul 10. Review.

PMID:
25013155
13.

Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.

Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gómez M, Conesa A, Lozano-Rubí R, Sánchez-Dalmau B, Alonso A, Villoslada P.

J Neurol. 2014 Apr;261(4):759-67. doi: 10.1007/s00415-014-7266-2. Epub 2014 Feb 16.

PMID:
24532201
14.

Colour vision impairment is associated with disease severity in multiple sclerosis.

Martínez-Lapiscina EH, Ortiz-Pérez S, Fraga-Pumar E, Martínez-Heras E, Gabilondo I, Llufriu S, Bullich S, Figueras M, Saiz A, Sánchez-Dalmau B, Villoslada P.

Mult Scler. 2014 Aug;20(9):1207-16. doi: 10.1177/1352458513517591. Epub 2014 Jan 7.

PMID:
24399824
15.

Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2014 Jan;75(1):98-107. doi: 10.1002/ana.24030. Epub 2014 Jan 2.

PMID:
24114885
16.

Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis.

Marro M, Taubes A, Abernathy A, Balint S, Moreno B, Sanchez-Dalmau B, Martínez-Lapiscina EH, Amat-Roldan I, Petrov D, Villoslada P.

J Biophotonics. 2014 Sep;7(9):724-34. doi: 10.1002/jbio.201300101. Epub 2013 Sep 6.

PMID:
24019106
17.

Retinal periphlebitis is associated with multiple sclerosis severity.

Ortiz-Pérez S, Martínez-Lapiscina EH, Gabilondo I, Fraga-Pumar E, Martínez-Heras E, Saiz A, Sanchez-Dalmau B, Villoslada P.

Neurology. 2013 Sep 3;81(10):877-81. doi: 10.1212/WNL.0b013e3182a3525e. Epub 2013 Jul 31.

18.

Retrograde retinal damage after acute optic tract lesion in MS.

Gabilondo I, Sepúlveda M, Ortiz-Perez S, Fraga-Pumar E, Martínez-Lapiscina EH, Llufriu S, Solá N, Saiz A, Sanchez-Dalmau B, Villoslada P.

J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):824-6. doi: 10.1136/jnnp-2012-304854. Epub 2013 May 28. No abstract available.

PMID:
23715916
19.

Nystagmus: an uncommon neurological manifestation of thiamine deficiency as a serious complication of sleeve gastrectomy.

Moizé V, Ibarzabal A, Sanchez Dalmau B, Flores L, Andreu A, Lacy A, Vidal J.

Nutr Clin Pract. 2012 Dec;27(6):788-92. doi: 10.1177/0884533612453746. Epub 2012 Oct 5.

PMID:
23042832
20.

Blind runner.

Pelegrín L, Mesquida M, Rey A, Sánchez-Dalmau B, Frohman L.

Surv Ophthalmol. 2012 Sep;57(5):486-94. doi: 10.1016/j.survophthal.2011.06.004. Epub 2011 Oct 21.

PMID:
22018675

Supplemental Content

Loading ...
Support Center